Literature DB >> 24270122

Prostate cancer: diffusion-weighted imaging versus dynamic-contrast enhanced imaging for tumor localization-a meta-analysis.

Mohammad Haghighi1, Shivam Shah, Samir S Taneja, Andrew B Rosenkrantz.   

Abstract

PURPOSE: The purpose of this study was to compare the diagnostic performance of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) imaging for prostate cancer (PCa) detection by performing a meta-analysis of studies evaluating these techniques within the same patient cohort.
METHODS: Evidence-based online databases were searched for studies reporting the performance of DWI and DCE in PCa detection in the same patient cohorts using histopathology as reference standard and providing sufficient data to construct 2 × 2 contingency tables. Pooled estimates of diagnostic performance were computed across included studies.
RESULTS: Of 80 initial studies identified, 5 studies (total of 265 patients and 1730 prostatic regions) met criteria for inclusion in the meta-analysis. Pooled sensitivity was 58.4% (95% confidence interval [CI], 53.5%-63.1%) for DWI and 55.3% (95% CI, 50.4%-60.1%) for DCE. Pooled specificity was 89.0% (95% CI, 87.2%-0.7%) for DWI and 87.9% (95% CI, 86.0%-89.6%) for DCE. At summary receiver-operating-characteristic analysis, area-under-the-curve was 0.810 (0.059) for DWI and 0.786 (0.079) for DCE. Heterogeneity across studies was high for sensitivity and specificity [inconsistency index (I), >90%], although heterogeneity of specificity was substantially improved after excluding an outlier study in terms of diagnostic threshold (I = 0.0%-68.8%). Relative performance of DWI and DCE remained similar after this exclusion
CONCLUSIONS: There was a paucity of studies comparing DWI and DCE in the same patient cohorts, and heterogeneity among these studies was substantial. Nevertheless, performance of DWI and DCE was similar across identified studies, with both techniques showing substantially better specificity than sensitivity. Larger studies with uniform methodology are warranted to further understand relative merits of the 2 techniques.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24270122     DOI: 10.1097/RCT.0b013e3182a3f9c7

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  15 in total

1.  Meta-analysis of diffusion-weighted magnetic resonance imaging in identification of colorectal cancer.

Authors:  Hongyuan Jia; Xuelei Ma; Yang Zhao; Jingyi Zhao; Rongjun Liu; Zihang Chen; Jinna Chen; Jingwen Huang; Yanyan Li; Jing Zhang; Feng Wang
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI.

Authors:  Andreas M Hötker; Yousef Mazaheri; Ömer Aras; Junting Zheng; Chaya S Moskowitz; Tatsuo Gondo; Kazuhiro Matsumoto; Hedvig Hricak; Oguz Akin
Journal:  AJR Am J Roentgenol       Date:  2016-02-22       Impact factor: 3.959

3.  IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model.

Authors:  Devkumar Mustafi; Sophie-Charlotte Gleber; Jesse Ward; Urszula Dougherty; Marta Zamora; Erica Markiewicz; David C Binder; Tatjana Antic; Stefan Vogt; Gregory S Karczmar; Aytekin Oto
Journal:  AJR Am J Roentgenol       Date:  2015-09       Impact factor: 3.959

4.  Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.

Authors:  Andreas M Hötker; Yousef Mazaheri; Junting Zheng; Chaya S Moskowitz; Joshua Berkowitz; Joshua E Lantos; Xin Pei; Michael J Zelefsky; Hedvig Hricak; Oguz Akin
Journal:  Eur Radiol       Date:  2015-03-29       Impact factor: 5.315

Review 5.  PI-RADS v2: Current standing and future outlook.

Authors:  Clayton P Smith; Barış Türkbey
Journal:  Turk J Urol       Date:  2018-05-01

6.  Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of prostate cancer: A Cancer Care Ontario clinical practice guideline.

Authors:  Masoom A Haider; Xiaomei Yao; Andrew Loblaw; Antonio Finelli
Journal:  Can Urol Assoc J       Date:  2017-01-12       Impact factor: 1.862

Review 7.  Imaging biomarkers in prostate cancer: role of PET/CT and MRI.

Authors:  M Picchio; P Mapelli; V Panebianco; P Castellucci; E Incerti; A Briganti; G Gandaglia; M Kirienko; F Barchetti; C Nanni; F Montorsi; L Gianolli; S Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-17       Impact factor: 9.236

Review 8.  The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis.

Authors:  Chen Jie; Liu Rongbo; Tan Ping
Journal:  Eur Radiol       Date:  2014-05-28       Impact factor: 5.315

Review 9.  Will Multi-Parametric Magnetic Resonance Imaging be the Future Tool to Detect Clinically Significant Prostate Cancer?

Authors:  Gianluca Giannarini; Michele Zazzara; Marta Rossanese; Vito Palumbo; Martina Pancot; Giuseppe Como; Maria Abbinante; Vincenzo Ficarra
Journal:  Front Oncol       Date:  2014-11-04       Impact factor: 6.244

Review 10.  Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy.

Authors:  Flavio Barchetti; Valeria Panebianco
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.